Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
* * $VICL Video Chart 08-30-2019 * *
Link to Video - click here to watch the technical chart video
"Take a look at me know".... Looks like people are anticipating the formal completion of the merger.
* * $VICL Video Chart 06-03-2019 * *
Link to Video - click here to watch the technical chart video
Plunging this one under a buck - showing approx. 2.35 netcash w/a (.25) quarterly burn.
Was this the cause of the recent dumpoff?
https://ih.advfn.com/stock-market/NASDAQ/vical-VICL/stock-news/79049132/statement-of-changes-in-beneficial-ownership-4
VICL
Ongoing trial completion date December 19, 2019.
Echo20
VICL
VICL keeps buying and selling.
Some potentials there.
Up tp $1.23 now?
Echo20
Klinsmann
Looks like VICL could have some potentials.
Echo20
Klinsmann
Just to see if you have any added information. Not insider information.
Thanks.
Echo20
Zorry, no insider information. Just charts and possible reversal is what I´m looking for, best combined with positive news ;)
Klinsmann
Do you see any good news and results in the near future?
Echo20
Bullish chart but volume missing...
Klinsmann
Moving up slightly!
Echo20
Thx! I still like the setup here - may need some more patience. There´re better stocks out there right now, but VICL gonna have its days imo
GLTY, added a person mark
Klinsmann
Best of success.
Any better news?
Echo20
Still here my friend. Gonna enter, looking strong. Stock success is seldom a matter of ihub posts, not much helpful information on such boards.
Klinsman
Huh?
Not many posters here this year.
Echo20
On close watch, gonna last some time to settle and reverse...
Any one here?
Vicl going up?
Echo20
Mostly corporate investments?
Echo2o
VICL
Notice these posts are all very old?
Is VICL corporate only now?
Echo20
That +150k buy block on Friday....well well well....that buyer imo knew about todays news.
Any Happy New Year's projections for VICL?
Echo20
2 fiddy by EOW
Is vicl going up now?
How far?
Echo20
Grand Master's
Going up?
Echo20
Chart lookin good!
INTL
Go VICL and SANJAY.
Echo20
goodplenty100
Big win for VICL and Sanjay.
Echo20
Opinionator
Great news. Keep it up VICL.
Antifungal formulas will be super valuable with all of the superbugs occurring.
Echo20
BUY HOLD BUY HOLD BUY HOLD ACCUMULATE
ONLY UPWARDS TRENDS FOR REST OF YEAR
STILL TONS OF CASH TO BURN AND REVENUES COMING IN SOON
Price will settle
with a continuous move up. Target of $5.00 within a year
I got alerted late about the news .. still I feel good that I got in at 3.29 .. looking for some action above 4$
I got lucky and got Dec 3 calls for .10 today!
VICL Over 20 times the average volume. Float is under 9 million. Regular trading day volume could be huge. Currently on level 2 (within 15 cent range) showing 2900 on the bid and over 35k on the ask.
Wow up big time AH. 1 m vol.
Yes
Like the setup on this one.
I got in today just in the nick of time!
VICL Low float monster with big catalyst AH. Past runner. CC tomorrow at noon.
VICL Bids stacking up AH. Big news! Bullish
https://ih.advfn.com/p.php?pid=nmona&article=75772622
Tough
Are the new products any good?
Echo20
It's all about selling on the news I would assume. Looking forward to a return to the upside.
Shareholders may need to worry about support levels, not resistance.
Followers
|
58
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1016
|
Created
|
05/23/06
|
Type
|
Free
|
Moderators |
Vical's proprietary core technology is based on plasmid DNA (pDNA), closed loops of DNA that encode any protein of interest. When injected into tissues such as skeletal muscle or the skin, cells take up pDNA and produce the encoded protein. This allows for pDNA to be used as the basis for a broad range of biopharmaceutical products: infectious disease vaccines (delivering antigens from viruses, bacteria, or parasites), cancer vaccines or immunotherapeutics (delivering tumor antigens or immunostimulatory proteins), and growth factors to stimulate angiogenesis and tissue repair in diseases such as cardiovascular disorders.
Since its initial discovery, Vical has continued to improve its DNA delivery technology so as to maximize gene expression as well as the body's response to the proteins produced. For example, we optimize the DNA sequences that make up our pDNA, and we continue to develop new formulation and delivery technologies, including the use of lipid molecules (which can function as vaccine adjuvants) and synthetic polymers such as poloxamers.
Plasmids are manufactured in Vical's cGMP facility in San Diego using uniform methods of bacterial fermentation and processing, which allows faster development and production times than technologies that require development of product-specific processes. In addition, since our product candidates contain no viral components they are designed to avoid unwanted immune responses, infections, or malignant changes in a cell's genetic makeup, and have been administered repeatedly with a very favorable safety profile in clinical trials to date.
http://www.vical.com/technology/vaxfectin/default.aspx
http://www.vical.com/technology/publications/default.aspx
Vical has filed thirteen investigational new drug applications to conduct clinical trials and holds four master files for manufacturing recombinant DNA products.
Vical has completed more than thirty clinical trials with recombinant DNA products. These Phase 1 – Phase 3 trials of vaccines or gene therapy products have been conducted in up to 15 countries.
Check back frequently for updates on future enrollments or connect with us through or connect with us on or .
Phase 3 Clinical Trial: ASP0113 Therapeutic Cytomegalovirus (CMV) Vaccine
A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT). For more information, please go to the NCT01877655 trial listing at ClinicalTrials.gov.
Phase 2 Clinical Trial: ASP0113 Therapeutic Cytomegalovirus (CMV) Vaccine 1
A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor. For more information, please go to the NCT01974206 trial listing at ClinicalTrials.gov.
Phase 1/2 Clinical Trial: Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 Therapeutic DNA Vaccines in Symptomatic HSV-2-Seropositive Adults. For more information, please go to the NCT02030301 trial listing at ClinicalTrials.gov. ?
$VICL recent news/filings
Many thanks to stocktrademan for post #774
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |